| Amount | Holding |
|---|---|
| 4.49% | Merck & Co Inc |
| 4.06% | Novartis AG ADR |
| 3.46% | UnitedHealth Group Inc |
| 3.08% | AstraZeneca PLC |
| 3.05% | Abbott Laboratories |
| 2.75% | Thermo Fisher Scientific Inc |
| 2.60% | Roche Holding AG Dividend Right Cert. |
| 2.56% | Humana Inc |
| 2.54% | Bristol-Myers Squibb Company |
| 2.45% | Boston Scientific Corp |
| 2.44% | AbbVie Inc |
| 2.36% | Sanofi SA |
| 2.19% | Vertex Pharmaceuticals Inc |
| 1.94% | Neurocrine Biosciences Inc |
| 1.90% | Gilead Sciences Inc |
| 1.86% | Biontech Ag |
| 1.83% | Centene Corp |
| 1.76% | Johnson & Johnson |
| 1.70% | Eli Lilly and Co |
| 1.63% | Elanco Animal Health Inc |
| 1.52% | Danaher Corp |
| 1.44% | Catalent Inc |
| 1.41% | Takeda Pharmaceutical Co Ltd |
| 1.37% | Anthem Inc |
| 1.27% | Novo Nordisk A/S B |
Expense Ratio Rating
5 /10
Expense Rating
1 /10
Market Score
9 /10
Category Score
0 /10
Market Size
9 /10
$JAGLX Alternatives
46%
FI Score
- jaglx
- Mutual Fund
- Sector Equity
- Healthcare
Janus Henderson Global Life Sciences Fund Class T
Expenses: 0.91% (Better than 0% of similar funds)
This is a bad choice for a Healthcare Sector Equity fund. See why ยป